282 related articles for article (PubMed ID: 34352380)
1. Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy.
Mikubo M; Inoue Y; Liu G; Tsao MS
J Thorac Oncol; 2021 Nov; 16(11):1798-1809. PubMed ID: 34352380
[TBL] [Abstract][Full Text] [Related]
2. Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer.
Delahaye C; Figarol S; Pradines A; Favre G; Mazieres J; Calvayrac O
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681591
[TBL] [Abstract][Full Text] [Related]
3. Persister cell plasticity in tumour drug resistance.
McDonald PC; Dedhar S
Semin Cell Dev Biol; 2024 Mar; 156():1-10. PubMed ID: 37977107
[TBL] [Abstract][Full Text] [Related]
4. Diapause-like Drug-Tolerant Persister State: The Key to Nirvana Rebirth.
Chen HL; Jin WL
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399515
[TBL] [Abstract][Full Text] [Related]
5. Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy.
Rehman SK; Haynes J; Collignon E; Brown KR; Wang Y; Nixon AML; Bruce JP; Wintersinger JA; Singh Mer A; Lo EBL; Leung C; Lima-Fernandes E; Pedley NM; Soares F; McGibbon S; He HH; Pollet A; Pugh TJ; Haibe-Kains B; Morris Q; Ramalho-Santos M; Goyal S; Moffat J; O'Brien CA
Cell; 2021 Jan; 184(1):226-242.e21. PubMed ID: 33417860
[TBL] [Abstract][Full Text] [Related]
6. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer.
Cabanos HF; Hata AN
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071428
[TBL] [Abstract][Full Text] [Related]
7. A prognostic model of drug tolerant persister-related genes in lung adenocarcinoma based on single cell and bulk RNA sequencing data.
Du Z; Zhang T; Lin Y; Dong G; Li A; Wang Z; Zhang Y; Giamas G; Stebbing J; Zhu L; Peng L
Heliyon; 2023 Nov; 9(11):e20708. PubMed ID: 37920509
[TBL] [Abstract][Full Text] [Related]
8. Drug-Tolerant Persister Cells in Cancer Therapy Resistance.
Dhanyamraju PK; Schell TD; Amin S; Robertson GP
Cancer Res; 2022 Jul; 82(14):2503-2514. PubMed ID: 35584245
[TBL] [Abstract][Full Text] [Related]
9. [Survival Mechanisms of Drug Tolerant Persister Cancer Cells against Targeted Anticancer Drugs].
Taoka M; Makimoto G; Ohashi K
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1239-1245. PubMed ID: 38247057
[TBL] [Abstract][Full Text] [Related]
10. Targeting Cancer Cell Dormancy.
Recasens A; Munoz L
Trends Pharmacol Sci; 2019 Feb; 40(2):128-141. PubMed ID: 30612715
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy.
Zhang Z; Qin S; Chen Y; Zhou L; Yang M; Tang Y; Zuo J; Zhang J; Mizokami A; Nice EC; Chen HN; Huang C; Wei X
EMBO Mol Med; 2022 Feb; 14(2):e14903. PubMed ID: 35023619
[TBL] [Abstract][Full Text] [Related]
12. Redox signaling in drug-tolerant persister cells as an emerging therapeutic target.
Zhang Z; Tan Y; Huang C; Wei X
EBioMedicine; 2023 Mar; 89():104483. PubMed ID: 36827719
[TBL] [Abstract][Full Text] [Related]
13. Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy.
Swayden M; Chhouri H; Anouar Y; Grumolato L
Cells; 2020 Dec; 9(12):. PubMed ID: 33291749
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic adaptations in drug-tolerant tumor cells.
Mani N; Daiya A; Chowdhury R; Mukherjee S; Chowdhury S
Adv Cancer Res; 2023; 158():293-335. PubMed ID: 36990535
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional signature of early cisplatin drug-tolerant persister cells in lung adenocarcinoma.
Chavez-Dominguez R; Aguilar-Cazares D; Perez-Medina M; Avila-Rios S; Soto-Nava M; Mendez-Tenorio A; Islas-Vazquez L; Benito-Lopez JJ; Galicia-Velasco M; Lopez-Gonzalez JS
Front Oncol; 2023; 13():1208403. PubMed ID: 37916165
[TBL] [Abstract][Full Text] [Related]
16. Immune cells in residual disease and recurrence.
Ceyhan Y; Garcia NMG; Alvarez JV
Trends Cancer; 2023 Jul; 9(7):554-565. PubMed ID: 37150627
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological agents targeting drug-tolerant persister cells in cancer.
Chen YC; Gowda K; Amin S; Schell TD; Sharma AK; Robertson GP
Pharmacol Res; 2024 May; 203():107163. PubMed ID: 38569982
[TBL] [Abstract][Full Text] [Related]
18. Drug Tolerant Cells: An Emerging Target With Unique Transcriptomic Features.
Niveditha D; Sharma H; Sahu A; Majumder S; Chowdhury R; Chowdhury S
Cancer Inform; 2019; 18():1176935119881633. PubMed ID: 31636480
[TBL] [Abstract][Full Text] [Related]
19. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.
Ramirez M; Rajaram S; Steininger RJ; Osipchuk D; Roth MA; Morinishi LS; Evans L; Ji W; Hsu CH; Thurley K; Wei S; Zhou A; Koduru PR; Posner BA; Wu LF; Altschuler SJ
Nat Commun; 2016 Feb; 7():10690. PubMed ID: 26891683
[TBL] [Abstract][Full Text] [Related]
20. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
